Clinical Trial

Trial of JYB1904 Injection in Adolescent Participants

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This Phase Ib Trial is Meant to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity Profiles of JYB1904 Injection in Adolescent Participants With Allergic Diseases.
Trial Details
NCT Number NCT07513857
Lead Sponsor Jemincare
Conditions Allergic Diseases
Enrollment 12 participants
Start Date 2026-05-17
Primary Completion 2027-07-30 (estimated)
Study Completion 2027-07-30 (estimated)
Updated on ClinicalTrials.gov 2026-04-07